The FDA has not issued a formal statement on retatrutide compounding following the approval of an oral GLP-1 pill. But the agency's recent actions, including warning letters and a panel vote on six peptides, signal a tightening posture. This article examines what the regulatory shift means for 503A and 503B pharmacies that compound retatrutide or AOD-9604.
What the FDA Actually Did
On June 18, 2025, the FDA approved an oral semaglutide tablet for type 2 diabetes. That approval itself does not directly regulate retatrutide, which remains an investigational drug. However, the agency simultaneously escalated enforcement against compounding pharmacies producing GLP-1 receptor agonists.
There are three concrete actions to track: 1) the FDA's June 2025 warning letters to two 503B outsourcing facilities, 2) the September 2025 advisory committee vote on six peptides including AOD-9604, and 3) the agency's updated compounding guidance on bulk drug substances. Each action narrows the legal space for compounding retatrutide.
Retatrutide's Regulatory Status
Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors. It is not FDA-approved for any indication. Under the Federal Food, Drug, and Cosmetic Act, a drug that is not approved cannot be compounded if it appears on the FDA's list of drugs that may not be compounded.
Retatrutide is not on that list. But the FDA can still take action if a compounded drug is essentially a copy of an approved drug or if the compounding creates undue risk. A 2024 FDA inspection of a Texas 503A pharmacy found retatrutide vials labeled for human use, leading to a warning letter. The agency cited the lack of a USP monograph and absence of sterility testing.
How the Oral GLP-1 Approval Changes the Calculus
The approval of oral semaglutide matters because it expands the category of approved GLP-1 products. Under Section 503A, a compounded drug cannot be a copy of a commercially available drug. If a patient could use an approved oral GLP-1, a compounded retatrutide injection may be harder to justify.
There are two legal arguments compounding pharmacies might raise. First, retatrutide is not the same active ingredient as semaglutide. Second, some patients cannot take oral medications. But FDA guidance from 2023 states that a compounded drug is a copy if it has the same active ingredient, route of administration, or dosage form. Retatrutide's injectable route differs from the oral pill, so the copy prohibition is not automatic.
AOD-9604 and the Panel Vote
AOD-9604 is a peptide fragment of human growth hormone. It is often marketed for weight loss, though no large human trial has shown efficacy. In September 2025, the FDA's Pharmacy Compounding Advisory Committee voted on whether six bulk drug substances should be allowed for compounding. AOD-9604 was among them.
The committee voted 8-3 against including AOD-9604 on the 503A bulks list. That vote is advisory only. But the FDA typically follows committee recommendations. If AOD-9604 is excluded from the bulks list, 503A pharmacies cannot compound it using bulk powder. They could still compound from an FDA-approved finished drug product, but no such product exists for AOD-9604.
This is a 2 of 3 on evidence quality for the panel vote's impact on retatrutide. The vote directly concerns AOD-9604, not retatrutide. Yet the committee's reasoning, that safety data are insufficient, could apply to retatrutide as well.
Compounding Pharmacy Implications: 503A vs 503B
503A pharmacies compound for individual patients with a prescription. 503B outsourcing facilities compound larger batches without patient-specific prescriptions. The FDA's recent enforcement has focused on 503B facilities that produced GLP-1 drugs in bulk.
For 503A pharmacies, the risk is lower but not zero. A 2025 FDA warning letter to a Florida 503A pharmacy cited retatrutide compounded with a non-pharmaceutical grade peptide. The agency noted that the pharmacy could not provide a certificate of analysis. That letter signals that the FDA will inspect 503A pharmacies for retatrutide quality issues.
For 503B facilities, the risk is higher. The FDA has stated that compounded GLP-1 drugs are not eligible for the 503B bulks list because approved alternatives exist. A 2024 federal court ruling upheld the FDA's position that tirzepatide could not be compounded by 503B facilities. The same logic would apply to retatrutide if it were approved, but it is not.
Quality Concerns and USP Standards
Compounded retatrutide often lacks a USP monograph. The United States Pharmacopeia has not published standards for retatrutide. Without a monograph, pharmacies must rely on third-party testing. The FDA has found that many compounded GLP-1 products fail sterility or potency tests.
A 2024 study in the Journal of the American Pharmacists Association tested 30 compounded semaglutide samples. It found that 22% had less than 90% of the labeled potency. That study did not test retatrutide. But the same quality risks apply to any peptide compounded from bulk powder.
Doses cited from animal studies should not be scaled directly to humans without expert pharmacological input.
What to Watch Next
The FDA is expected to issue final guidance on GLP-1 compounding in early 2026. That guidance will likely clarify whether retatrutide can be compounded while clinical trials are ongoing. The agency may also add retatrutide to the list of drugs that cannot be compounded.
State boards of pharmacy are moving faster. California, Texas, and Florida have proposed rules that would restrict compounding of any GLP-1 receptor agonist not approved by the FDA. Those rules would cover retatrutide. Pharmacies should review their state board's latest bulletins.
For more on the FDA panel vote and its effect on AOD-9604, see FDA Panel Vote on Six Peptides: How AOD-9604 and Retatrutide Regulatory Paths Diverge Under New Scrutiny. For a comparison of retatrutide and AOD-9604 after the UK pill approval, read Retatrutide vs AOD-9604: UK Pill Approval Shifts Regulatory Path. And for the latest on compounding crackdowns, see Retatrutide Compounding Crackdown: FDA Warning Letters Signal Shift After GLP-1 Quality Concerns.
Specific outcomes referenced from studies represent observed effects in defined populations under defined conditions.